Global

News Releases

This section features all recent CSL Behring news releases. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

All Releases

15 November 2016 CSL Behring Presents Positive Results from the CSL112 AEGIS-I Phase 2b Trial

AEGIS-1 Phase 2b study meets co-primary endpoints of hepatic and renal safety and demonstrates proof of mechanism - results were presented at AHA 2016.

> Read More
14 November 2016 AFSTYLA®, for Haemophilia A, Receives Positive Opinion from European Medicines Agency CHMP

Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for AFSTYLA® [Recombinant Human Coagulation Factor VIII, Single Chain] for patients with haemophilia A.

> Read More
27 October 2016 CSL Behring Receives 2016 Marcum Innovator Breakthrough Award for Pioneering New Advancements in the Biotech/Healthcare Field

One of the world’s top specialty biotherapeutics companies, CSL Behring continues to introduce innovations to address unmet medical needs or enhance current treatments.

> Read More
07 October 2016 Many Rare Disease Patients Would Not Have Treatments Available to Them without an Adequate Supply of Human Plasma

Many Rare Disease Patients Would Not Have Treatments Available to Them without an Adequate Supply of Human Plasma, and patients call plasma donors "heroes" for their lifesaving contributions.

> Read More
03 October 2016 Therapeutic Goods Administration Approves IDELVION® - CSL Behring’s Novel Recombinant Haemophilia B Treatment with up to 14-day Dosing Intervals

CSL Behring announced that the Australian Therapeutic Goods Administration (TGA) has approved IDELVION®[albutrepenonacog alfa] in patients with haemophilia B (congenital factor IX deficiency).

> Read More
Page 4 of 7 First | Previous | Next | Last

Share
LinkedIn Twitter Facebook Google+